Brief: Sienna Biopharma Announces First Patient Dosed In First-In-Human Trial Of Topical SNA-125

Sienna Biopharmaceuticals

14/02/2018 14:05

Feb 14 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O : 
    * SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN 
FIRST-IN-HUMAN TRIAL OF TOPICAL SNA-125 
    * SIENNA BIOPHARMACEUTICALS INC - TOP-LINE RESULTS FROM 
STUDY 
EXPECTED IN Q3 OF 2018 
    * SIENNA BIOPHARMACEUTICALS INC - PLAN TO INITIATE SNA-125 
PROOF-OF-CONCEPT TRIAL FOR ATOPIC DERMATITIS AND EXPECT THOSE 
DATA IN SECOND HALF OF 2018 
    * SIENNA BIOPHARMACEUTICALS- EXPECT TO REPORT TOP-LINE DATA 
IN 1H 
2019 FROM SNA-120 PHASE 2B CLINICAL TRIAL FOR PRURITUS & 
ASSOCIATED UNDERLYING PSORIASIS 
 
Source text for Eikon:  ID:nGNX6dWfL0  
Further company coverage:  SNNA.O  
 
 ((Bangalore.newsroom@thomsonreuters.com;))